EUBREAST 01 (R) Omission of sentinel lymph node biopsy in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy: a single-arm, prospective surgical trial.

Recruitment Closed 12/2024

Project Description

Omission of sentinel lymph node biopsy in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy: a single-arm, prospective surgical trial.

• PI: Oreste Gentilini, Toralf Reimer 
• study initiated by EUBREAST
• trial design: prospective, multi-center, single-arm (triple-negative and HER2-positive breast cancer)
• primary endpoint: 3-year axillary recurrence-free survival (ARFS) after neoadjuvant systemic therapy and lumpectomy (BCS) in initially cN0 patients

Data management and monitoring by the German Breast Group (GBG).

https://clinicaltrials.gov/study/NCT04101851

Publications

Abstract OT1-07-01: Omission of SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after NAST: a single-arm, prospective surgical trial (EUBREAST-01 trial, GBG 104) , AACR, Volume 83, Issue 5_Supplement

Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer:
Rationale for the Prospective, Multicentric EUBREAST-01 Trial, Review in Cancers, 2020, 3698